GH Research PLC
GHRS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001855129
No open-market purchases or sales by GH Research PLC insiders were filed in the last 90 days; 63 institutions reported holding it in 13F filings for Q2 2026, worth $1.38B in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding GH Research PLC changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 30 | 33 | +3 |
| Shares | 30.0M | 32.1M | +2.06M (+6.9%) |
| Value | $701.0M | $587.1M | −$113.8M (−16.2%) |
New holders (6)
Institutions that held GH Research PLC at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| DAFNA Capital Management LLC | 55,000 | $1.01M | 0.26% |
| Parametric Portfolio Associates LLC | 46,417 | $849.0K | 0.00% |
| Barclays PLC | 34,092 | $624.0K | 0.00% |
| Exchange Traded Concepts, LLC | 1,032 | $19.0K | 0.00% |
| UBS Group AG | 100 | $2.00K | 0.00% |
| Point72 Hong Kong Ltd | 80 | $1.00K | 0.00% |
Sold out (3)
Institutions that held GH Research PLC at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Ghost Tree Capital, LLC | 100,000 | $2.33M |
| Millennium Management LLC | 27,144 | $633.0K |
| Cubist Systematic Strategies, LLC | 300 | $7.00K |